Q BIOMED INC. (OTCQB:QBIO) CONGRATULATES
MANNIN RESEARCH ON SELECTION TO THE CHICAGO-CANADA MENTORSHIP PROGRAM (C2MP) AND
INAUGURAL MEETING
Mannin assigned world
class industry mentors and advisors
NEW YORK, March 17, 2016 - Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company
is pleased to congratulate Mannin Research on its selection to the C2MP program
and the exceptional mentors and advisors now included in the long list of
industry experts available to assist in advancing these important
technologies.
The C2MP program is a tailor-made mentoring program focused on life
science innovators. In partnership with the Chicago Innovation Mentors
(CIM@MATTER) organization, the Canadian Trade Commissioner Service will
catalyze and accelerate technology commercialization opportunities in the
Chicago area by matching experienced and supportive mentoring teams with early
stage innovators. Mannin Research was selected to take part in the program so
as to accelerate the development and commercialization of Mannin’s lead
indication, MAN-01 for Primary Open-Angle Glaucoma. CIM@MATTER was established
in 2010 based on the VMS program at the Massachusetts Institute of Technology.
CIM@MATTER has seven member institutions, and nearly 200 mentors as
part of its innovation network. The C2MP program has provided Mannin with a
mentor and a group of advisors from a team of life science and business
professionals within the CIM@MATTER team and dedicated support from the Trade
Commissioner Service of Canada.
Mannin’s lead mentor, David Kempner, has
more than 20 years of experience consulting on the business aspects of
biotechnology preceded by eight years of experience in a broad spectrum of
biological and biochemical research projects.
David is the founder and Managing Director of Integrated Market and
Technology Assessments Inc., a management consulting firm providing technical
market research and corporate/business development services to pharmaceutical,
diagnostic and biotechnology companies in the U.S. He was also the co-founder
and Executive VP Corporate development of NovaDx, a venture diagnostic firm
founded to identify novel diagnostic markers and develop through proof of
concept.
Michael Rosen is Managing Director of
Rosen Biosciences Strategies, a life science economic development consultancy
focusing on enabling international life science companies to enter the U.S.
market. Prior to this, he was Senior Vice President, New Business Development
for the Science + Technology Group at Forest City Enterprises. He has spent 20 years
in senior management positions with Pfizer, Bristol-Myers Squibb and
Searle/Monsanto, and spent 12 years as President/CEO of European and U.S.
biotech and medical device companies in the areas of cancer, neuroscience,
woundcare and kidney disease. Mr. Rosen is a founder, former Vice-Chairman and
current board member of the Illinois Biotechnology Industry Organization.
Gayle Kirkpatrick is an accomplished
business development executive with 20+ years of experience in Fortune 100
healthcare corporations and major academic research institutions. She has
led due diligence for numerous pipeline and company acquisitions, and has
expertise in technology transfer, licensing, acquisitions, strategic alliances,
and venture investment. She has held senior positions at Astellas and
AbbVie/Abbott and has served on several boards including chair of the
BioForward board (the Wisconsin state affiliate organization of BIO).
Catherine Sazdanoff is a global
healthcare executive with experience in leadership roles across corporate
development, business development, operations, legal and risk management. She
has a JD from Northwestern University and has held senior positions at Abbot
Laboratories, and Takeda Pharmaceuticals. Catherine is also a member of the
board of Meridian Bioscience Inc. and an advisor to mProve Health, LLC.
Kris Rothleutner, is an experienced
pharmaceutical industry professional and successful entrepreneur. He is
currently the Director of Life Cycle Management (Orphan Business Unit) at
Horizon Pharma, and has held senior positions at Takeda Pharmaceuticals, and
has also worked with Abbot Laboratories.
Mannin’s CEO, Dr. George N. Nikopoulos stated. “We are thrilled to be
apart of the program. We see the value in the acceleration process as it relates
to our development and commercialization milestones. We thank the Canadian
Trade Commissioner Service in Chicago for their support and look forward to a
successful program.”
In October 2015 Q BioMed Inc. entered into an agreement with Mannin
Research to exclusively license, with an option to acquire, the platform
technology assets of Mannin Research, the developer of a new class of vascular
therapeutics. Mannin’s primary focus is developing a first-in-class therapeutic
eye-drop for glaucoma in adults and children, using a research platform
designed to help develop new drugs for that indication and cystic kidney
disease, among other diseases. Lead drug candidate MAN-01 is designed to treat
abnormal vessels within the eye—thus treating glaucoma at its root causes.
We invite our shareholders and interested parties to subscribe to our
email list and stay informed on our website at www.qbiomed.com and follow us on
the social media feeds we use.
About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and
development company. We are focused on acquiring companies and biomedical
assets. Q is dedicated to providing these target companies and assets,
strategic resources, developmental support, and expansion capital to ensure
they meet their developmental potential enabling them to provide products to patients
in need.
Forward-Looking
Statements:
This
press release may contain “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and
any other statements that are not historical facts. Forward-looking statements
are based on management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause actual results to
differ materially from those currently anticipated are: risks related to our
growth strategy; risks relating to the results of research and development
activities; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to
attract, integrate, and retain key personnel; the early stage of products under
development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward looking
statements contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such statement is
based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
Source:
Q BioMed Inc.
Sign
up for the free investor news and stock alerts:
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained
investorideas.com for PR, media, news publication and social media effective
February 5th for three months: two thousand five hundred per month.
Additional
info regarding BC Residents and global Investors: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
